Foghorn Therapeutics Inc.: stock overview

FHTXNASDAQHealthcare · Pharmaceutical Preparations

Price

$2.07

November 13, 2026Market cap $122M

DCF calculator

What Ploutos Investor adds for Foghorn Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

In short

Foghorn Therapeutics had revenue of $112M over the last 12 months and net income of $9.4M, a net margin of 8.4%. Revenue grew by 135.1% a year on average over the last 5 years. At $2.07 the shares trade at a P/E of 21.3. It holds more cash than debt, by $80M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$122M
58.70M shares
P/E
21.3
Revenue, 12 months
$112M
+135.1% a year over 5 years
Net margin
8.4%
2025: -240.3%, above 6% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

-4.9% a year over 2 years

Fiscal years in figures

FHTX's revenue, profit, cash flow and dividend with each year-end price, from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $275M
$122M
Enterprise value 
$41M
P/E 
21.3
EV / EBIT 
17.3
EV / Revenue 
0.4
P/B 
–
FCF yield 3-year median: -38.6%
–
Earnings yield 3-year median: -33.5%
4.7%

Profitability

Operating margin 
2.1%
Net margin 3-year median: -288.2%
8.4%
ROIC 
–
ROIC, 5-year average 
-82.2%
ROE 
–

Growth

Revenue, yearly change 
+36.8%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+135.1%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$80M
Total debt 
$44M
Of which operating leases 
$44M
Net cash 
$80M
Net debt / EBITDA 
-14.1x
Interest cover 
–
Current ratio 
4.24

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+5.6%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

-279.5%

Above 5% of the 285 companies in its industry, and 1% of all.

Net margin

-240.3%

Above 6% of the 302 companies in its industry, and 1% of all.

ROA

-37.5%

Above 15% of the 313 companies in its industry, and 5% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Foghorn Therapeutics Inc.
CIK
1822462
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
58.70M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Foghorn Therapeutics's filings show?

These are Foghorn Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about FHTX

Didn't find what you were looking for?

Ask us
What is FHTX's market cap?

Foghorn Therapeutics Inc.'s market cap is $122M, at a price of $2.07 on November 13, 2026 and 58.70M shares.

What is FHTX's P/E?

FHTX's P/E is 21.3, on earnings per share of $0.10 over the last 12 months.

How much revenue does FHTX have?

Foghorn Therapeutics had revenue of $112M over the last 12 months. Over the last 5 years it changed by +135.1% a year on average.

Does FHTX pay a dividend?

No. Foghorn Therapeutics paid no regular dividend over the last 12 months.

Where do the figures come from?

From Foghorn Therapeutics Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.